Research progress on biomarkers of diabetic nephropathy

doi:10.16352/j.issn.1001-6325.2025.04.0546

Abstract

Abstract: Diabetic nephropathy (DN) is one of the most common complications of diabetes, and has become the main cause of chronic kidney disease and end-stage renal disease worldwide. At present, the pathogenesis of DN is not completely clear. For a long time, the routine treatment of DN is a combination of life management, hypoglycemic, hypotensive with other symptom-based treatment, but its progress cannot be delayed. Therefore, early detection, diagnosis, and treatment of DN are particularly important, but there is currently no single indicator that can be used for early diagnosis of DN. Therefore, the development of simple, sensitive, and efficient biomarkers is becoming increasingly important.

Key words: diabetic nephropathy, biomarkers, diagnosis

CLC Number:

R446.1

ZHAO Qingqing, CHENG Xiaoliang. Research progress on biomarkers of diabetic nephropathy[J]. Basic & Clinical Medicine, 2025, 45(4): 546-550.

References

[1] Curovic VR, Eickhoff MK, Rönkkö T, et al. Dapagli-flozin improves the urinary proteomic kidney-risk classifier CKD273 in type 2 diabetes with albuminuria: a randomized clinical trial[J]. Diabetes Care,2022,45:2662-2668. doi: 10.2337/dc22-1157.
[2] Verbeke F, Siwy J, Van Biesen W, et al. The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease[J]. Nephrol Dial Transplant,2021,36:811-818. doi: 10.1093/ndt/gfz242.
[3] Rambabova-Bushljetik I, Metzger J, Siwy J, et al. Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients[J].Nephrol Dial Transplant,2022,37:2014-2021. doi: 10.1093/ndt/gfab297.
[4] Ali H, Malik MZ, Abu-Farha M, et al. Dysregulated urinary extracellular vesicle small RNAs in diabetic nephropathy: implications for diagnosis and therapy[J]. J Endocr Soc,2024,8:bvae114. doi: 10.1210/jendso/bvae114.
[5] Wang J, Tao Y, Zhao F, et al. Expression of urinary exosomal miRNA-615-3p and miRNA-3147 in diabetic kidney disease and their association with inflammation and fibrosis[J]. Ren Fail,2023,45:2121929. doi: 10.1080/0886022X.2022.2121929.
[6] Han Y, Zhou Q, Liu L, et al. DNI-MDCAP: improve-ment of causal MiRNA-disease association prediction based on deep network imputation[J]. BMC Bioinformatics,2024,25:22. doi: 10.1186/s12859-024-05644-6.
[7] Zheng S, Zeng Y, Chu L, et al. Renal tissue-derived exosomal miRNA-34a in diabetic nephropathy induces renal tubular cell fibrosis by promoting the polarization of M1 macrophages[J]. IET Nanobiotechnol,2024,2024:5702517. doi: 10.1049/2024/5702517.
[8] Zhou HL, Zhang R, Anand P, et al. Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury[J]. Nature,2019,565:96-100. doi: 10.1038/s41586-018-0749-z.
[9] Li D, Hsu FC, Palmer ND, et al. Multiomics analyses identify AKR1A1 as a biomarker for diabetic kidney disease[J]. Diabetes, 2024,73:1188-1195. doi: 10.2337/db23-0540.
[10] Fujii J, Homma T, Miyata S, et al. Pleiotropic actions of aldehyde reductase(AKR1A)[J]. Metabolites,2021,11:343. doi: 10.3390/metabo11060343.
[11] Petra E, Siwy J, Vlahou A, et al. Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease[J]. PLoS One,2022,17:e0262667. doi: 10.1371/journal.pone.0262667.
[12] Meng N, Li Y, Jiang P, et al. A comprehensive pan-cancer analysis of the tumorigenic role of matrix metallopeptidase 7(MMP7) across human cancers[J]. Front Oncol, 2022,12:916907. doi: 10.3389/fonc.2022.916907.
[13] Hirohama D, Abedini A, Moon S, et al. Unbiased human kidney tissue proteomics identifies matrix metalloprote-inase 7 as a kidney disease biomarker[J]. J Am Soc Nephrol, 2023,34:1279-1291. doi: 10.1681/ASN.0000000000000141.
[14] Zhou D, Tian Y, Sun L, et al. Matrix metalloproteinase-7 is a urinary biomarker and pathogenic mediator of kidney fibrosis[J]. J Am Soc Nephrol, 2017,28:598-611. doi: 10.1681/ASN.2016030354.
[15] Balu D, Krishnan V, Krishnamoorthy V, et al. Does serum kidney injury molecule-1 predict early diabetic nephropathy: A comparative study with microalbuminuria[J]. Ann Afr Med, 2022,21:136-139. doi: 10.4103/aam.aam_92_20.
[16] Khan FA, Fatima SS, Khan GM, et al. Evaluation of kidney injury molecule-1 as a disease progression biomarker in diabetic nephropathy[J]. Pak J Med Sci, 2019,35:992-996. doi: 10.12669/pjms.35.4.154.
[17] Siddiqui K, Joy SS, George TP, et al. Potential role and excretion level of urinary transferrin, KIM-1, RBP, MCP-1 and NGAL markers in diabetic nephropathy[J]. Diabetes Metab Syndr Obes, 2020,13:5103-5111. doi: 10.2147/DMSO.S282166.
[18] Prashant P, Dahiya K, Bansal A, et al. Neutrophil gelatinase-associated lipocalin(NGAL) as a potential early biomarker for diabetic nephropathy: a meta-analysis[J]. Int J Biochem Mol Biol,2024,15:1-7. doi: 10.62347/FVBS3902.
[19] Lin ZH, Dai SF, Zhao JN, et al. Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy[J]. World J Diabetes, 2023,14:883-891. doi: 10.4239/wjd.v14.i6.883.
[20] Lee E, Lee YK, Kang HJ. Association between the urinary N-acetyl-β-D-glucosaminidase/creatinine ratio and factors of the metabolic syndrome[J]. Ann Clin Lab Sci, 2018,48:627-633.
[21] Elsayed MS, El Badawy A, Ahmed A, et al. Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus[J]. Diabetes Metab Syndr, 2019,13:374-381. doi: 10.1016/j.dsx.2018.08.017.
[22] Dejenie TA, Abebe EC, Mengstie MA, et al. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus[J]. Front Endocrinol(Lausanne), 2023,14:1124367. doi: 10.3389/fendo.2023.1124367.
[23] Zhang L, Xue S, Wu M, et al. Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis[J]. Front Med(Lausanne), 2022,9:914587. doi: 10.3389/fmed.2022.914587.
[24] Ueno A, Onishi Y, Mise K, et al. Plasma angiotensin-converting enzyme 2(ACE2) is a marker for renal outcome of diabetic kidney disease(DKD)(U-CARE study 3)[J]. BMJ Open Diabetes Res Care,2024,12:e0042.doi: 10.1136/bmjdrc-2024-004237.